Lenalidomide and Rituximab combination for Treatment of MCL

• Ad ID #00023914
• Views 90
• Contact Person Mary Kudro
• Contact Number 18008891064
• Added on March 12, 2021
• Last Updated 3 years ago
• Location: belgium
• Price: Check with Seller
• https://ikrispharmanet.wixsite.com/blog/post/lenalidomide-plus-rituximab-for-treatment-of-mantle-cell-lymphoma

MCL is mantle cell lymphoma is an incurable disease. Lenalidomide and rituximab combination for the treatment of MCL is an immunomodulatory regimen that has shown positive activity in patients with indolent B-cell non-Hodgkin’s lymphoma. Lenalidomide and rituximab combination is useful for treating patients who have relapsed /refractory MCL. The patients who are progressive on this combinational treatment responded in favour of the subsequent therapeutic regimens.